Vanguard Capital Management’s Avalo Therapeutics AVTX Stock Holding History
Bought
Maintained
Sold
Other funds holding AVTX
Vanguard Capital Management's AVTX Position: Q3 2026 in Review
Vanguard Capital Management reduced its Avalo Therapeutics (AVTX) stake by 0.35% in Q3 2026, selling an estimated $147K and leaving 2,256,245 shares worth $34.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2091.
Vanguard Capital Management first reported a position in AVTX in Q1 2026 and has held it in 3 quarters since. The position peaked at $41.8M in Q2 2026. 148 funds tracked by Wall St. Rank hold AVTX as of Q3 2026.
- Vanguard Capital Management held 2,256,245 shares of Avalo Therapeutics worth $34.6M as of Q3 2026.
- Vanguard Capital Management sold 8,001 Avalo Therapeutics shares in Q3 2026, an estimated $147K.
- Avalo Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #2091 holding.
- Vanguard Capital Management first reported a position in Avalo Therapeutics in Q1 2026 and has held it in 3 quarters since.
- Vanguard Capital Management's Avalo Therapeutics position peaked at $41.8M in Q2 2026.
- 148 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q3 2026.
Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.